MedPath

Chinese Observational Prospective Study of Aging Population With Chronic Kidney Disease(C-OPTION)

Conditions
Chronic Kidney Disease
Registration Number
NCT03246204
Lead Sponsor
Chinese PLA General Hospital
Brief Summary

The study is an observational, multicenter, prospective cohort study aimed at evaluating a 5-year screening programme for chronic kidney disease(CKD) in a population of elderly patients, aged 65 years or more, in China.To analyze the etiology and composition spectrum, the incidence of complications and co-morbidities.To assess the correlation between daily living ability, mental and physical function, quality of life, nutritional status and prognosis.To develop biomarkers of renal aging.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
3000
Inclusion Criteria
  • age≥65 years
  • clinical diagnosis of CKD
  • signed informed consent
Exclusion Criteria
  • subjects who have a poor compliance and cannot be scheduled for follow-up
  • subjects participating in other interventional clinical trials
  • ESRD or dialysis
  • Acute kidney injury(AKI)
  • history of solid organ or bone marrow transplantation
  • active malignancy within 24 months prior to screening or metastatic cancer
  • life expectancy less than 6 months;
  • severe cognitive impairment(NYHA III or IV)
  • HIV infection or AIDS
  • subjects cannot be able to complete the assessment including dementia or other mental disorders, limited physical activity, severe visual impairment
  • simple hematuria

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Death5 year
Incidence of End Stage Renal Disease (ESRD)5 year

ESRD will be defined as estimated glomerular filtration rate(eGFR)\<15 mL/min/1.73 m2 or dialysis

eGFR decline≥40%5 year
Secondary Outcome Measures
NameTimeMethod
Heart failure5 year
Acute coronary syndrome5 year
Peripheral arterial disease5 year
Cerebral stroke5 year

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.